

MERGER ANNOUNCEMENT M/22/004 – EXPONENT/XEINADIN

Section 21 of the Competition Act 2002

Competition and Consumer Protection Commission clears proposed acquisition by Exponent Private Equity LLP of sole control of Xeinadin Group Limited

28 April 2022

The Competition and Consumer Protection Commission (the “Commission”) has today cleared the proposed transaction whereby Exponent Private Equity LLP would acquire sole control of Xeinadin Group Limited. The proposed transaction was notified under the Competition Act 2002, as amended, on 24 January 2022.

The Commission has formed the view that the proposed transaction will not substantially lessen competition in any market for goods or services in the State. The Commission will publish the reasons for its determination on its website no later than 60 working days after the date of the determination and after allowing the parties the opportunity to request that confidential information be removed from the published version.

Additional Information

Exponent Private Equity LLP (“Exponent”) is a limited liability partnership incorporated in England and Wales that makes private equity investments in businesses located in the United Kingdom, Ireland and across Europe. Exponent’s investments involve a range of different industry sectors, including healthcare, food, transportation, advertising, and finance.

Xeinadin Group Limited is a financially consolidated group of accounting firms spread across the UK and Ireland that is ultimately owned by individuals who work in its member offices. Xeinadin offers accounting and bookkeeping, payroll, tax, audit and business consulting (including corporate finance and restructuring) services to entrepreneurs, small or medium enterprises with less than 250 full-time employees and not-for-profit organisations.